Companies › Telix Pharmaceuticals (Innovations)
8 active drug programs in 11 registered trials: 5 Phase 3, 5 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| 177Lu-TLX250 | – | Phase 3 | ccRCC; Solid Tumor, Adult | Dec 2026 |
| 68Ga-PSMA-11 PSMA-targeting radioconjugate (Gallium-68 labeled PSMA ligand peptide conjugated via HBED- | FOLH1 | Phase 3 | PCA | Jan 2027 |
| TLX101-Tx Targeted radiopharmaceutical delivering radiation to glioblastoma cells | – | Phase 3 | Neoplastic Disease | Jul 2027 |
| 177Lu-TLX591 Lutetium-177 labeled anti-PSMA antibody-drug conjugate | FOLH1 | Phase 3 | Metastatic Castration-resistant Prostate Cancer | Dec 2027 |
| Girentuximab (TLX250) Carbonic anhydrase IX other | CA9 | Phase 3 | Clear Cell Renal Cell Carcinoma | – |
| 153Sm-DOTMP (TLX090-Tx) Samarium-153 bound to diethylenetriaminepentaacetic acid (DOTMP); radiopharmaceutical that | – | Phase 1 | Bone Pain | Apr 2027 |
| 131I-TLX-101 (131I-IPA) Radioiodine (131I)-labeled immunoconjugate targeting amino acid transporter; used with 18F | – | Phase 1 | Neoplastic Disease | Jun 2027 |
| 89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx) anti-PDGFRA antibody labeled with zirconium-89 for diagnostic imaging | PDGFRA | Phase 1 | Soft Tissue Sarcoma | Oct 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06750419 | Girentuximab (TLX250) | Phase 3 | Clear Cell Renal Cell Carcinoma | Oncology | Jun 2026 |
| NCT05868174 | 177Lu-TLX250 | Phase 1 | Solid Tumor, Adult | Oncology | Dec 2026 |
| NCT05868174 | 177Lu-TLX250 | Phase 1 | Solid Tumor, Adult | Oncology | Dec 2026 |
| NCT07052214 | 68Ga-PSMA-11 | Phase 3 | PCA | Oncology | Jan 2027 |
| NCT07197645 | 153Sm-DOTMP (TLX090-Tx) | Phase 1 | Bone Pain | Oncology | Apr 2027 |
| NCT05450744 | 131I-TLX-101 (131I-IPA) | Phase 1 | Neoplastic Disease | Oncology | Jun 2027 |
| NCT07100730 | TLX101-Tx | Phase 3 | Neoplastic Disease | Oncology | Jul 2027 |
| NCT07197580 | 177Lu-TLX250 | Phase 3 | ccRCC | Oncology | Aug 2027 |
| NCT06537596 | 89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx) | Phase 1 | Soft Tissue Sarcoma | Oncology | Oct 2027 |
| NCT06520345 | 177Lu-TLX591 | Phase 3 | Metastatic Castration-resistant Prostate Cancer | Oncology | Dec 2027 |
| NCT06447103 | Girentuximab (TLX250) | Phase 2 | Clear Cell Renal Cell Carcinoma | Oncology | Dec 2029 |
CSPC Megalith Biopharmaceutical BeiGene RemeGen Clarity Pharmaceuticals Hansoh BioMedical R&D Company
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.